KRAS expert opinion

With new medical developments, it is always valuable to hear the opinions of experts in the field. In this section of KRAS information, several thought leaders give their responses to common questions surrounding KRAS and KRAS testing.

Timothy Maughan

Professor Maughan is Consultant Clinical Oncologist in Cardiff, Wales and has specialized in GI cancers and lymphoma therapy. He has many years' experience in clinical trials in GI cancer.

Q1 How important do you perceive the use of biomarkers in the future of oncology?
Q2 Can you explain what KRAS is and what a KRAS mutation means?
Q3 What would the health economic benefits be from being able to target therapies more effectively?